Searched for
ANTI RETROVIRALS DRUGS
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...19 Jun, 2026, 11.50 AM IST- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...12 Jun, 2026, 12.25 PM IST
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...31 May, 2026, 01.34 PM IST
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...23 May, 2026, 10.24 PM IST
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...18 May, 2026, 10.31 PM IST
- Hetero launches FDC combination of key HIV drugsThe FDC drug ‘Darunavir+Ritonavir’ is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in ...14 Nov, 2017, 05.34 PM IST
- US FDA approves sale of Strides Arcolab's HIV treatment drugStrides Arcolab said US health regulator has approved its drug used for treating HIV infection in adult and children for sale in US market.15 May, 2015, 12.00 PM IST
- Cipla awarded $188.95 million tender by Global Fund for ARV drugs to treat HIV/AIDSCipla has been awarded $188.95 million tender for anti-retrovirals drugs by Global Fund which would enable it to supply the medicines to ov...13 Feb, 2015, 01.33 PM IST
- HIV fears rise as six states face severe shortage of condomsThe matter was recently raised with the Union health ministry, following which the health secretary met senior officials from the NACO.30 Jan, 2015, 11.39 AM IST
- Cipla to develop formulation for HIV +ve children with DNDiCipla will work to produce an appropriate 4-in-1 combination sachet product for easy mixing into food or liquids such as water, juice, or b...21 Jul, 2012, 07.34 PM IST
- Ranbaxy inks pact with Gilead for three generic HIV/AIDS drugsRanbaxy has entered into an agreement with US-headquartered Gilead Sciences to manufacture and market three new generic HIV/AIDS drugs.12 Jul, 2011, 02.47 PM IST
- Drugs by Indian cos reduces cost of HIV first line treatmentGeneric anti-retroviral drugs manufactured by Indian cos have brought down the cost of first line treatment for HIV patients from $800 to $...25 Aug, 2010, 09.24 PM IST
- New, more efficient anti-AIDS drug for untreated patientsMedical researchers on Sunday unveiled clinical trials of new anti-AIDS drug that better controls the spread of the deadly virus among prev...27 Oct, 2008, 08.58 AM IST
- 'Indian generic retrovirals for HIV patients more effective'India has commended the much cheaper generic versions being produced by its companies to help meet the shortfall.13 Jun, 2008, 09.03 PM IST
- Strides Arcolab gets US nod for anti-HIV drugPharmaceutical company, Strides Arcolab has received tentative approval from the United States Food and Drug Administration (USFDA) for Efa...28 Mar, 2007, 12.30 PM IST
- JB Chem ties up with US co for anti-HIV drugJB Chemicals & Pharmaceuticals Ltd on Friday said it has signed a non-exclusive license agreement with US-based Gilead Sciences Inc to manu...22 Sep, 2006, 04.00 PM IST
- Exports pump up Cipla net 53%Buoyed by higher exports and local sales, net profit of pharma firm Cipla rose 52.9% to Rs 170.4 crore for June quarter, reports Our Bureau...22 Jul, 2006, 02.30 AM IST
Load More
